Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959234 | 0.90 | NR1H2 (0.47) | KIF11PTGDR2TDO2CCNB2CDK1 | |
| SCHEMBL2959852 | 0.88 | KIF11 (0.42) | KIF11PTGDR2TDO2CCNB2CDK1 | |
| SCHEMBL317746 | 0.86 | PTGDR2 (0.53) | PTGDR2GSK3BCDK5CDK5R1EIF2AK2 | |
| SCHEMBL2961945 | 0.81 | NR1H2 (0.47) | PTGDR2NR1H2NR1H3EIF2AK2 | |
| SCHEMBL317661 | 0.79 | PTGDR2 (0.54) | KIF11PTGDR2NR1H2NR1H3 | |
| SCHEMBL2955003 | 0.76 | MAPK14 (0.47) | KIF11PTGDR2CCNB2CDK1CCNB1 | |
| SCHEMBL317801 | 0.76 | PTGDR2 (0.53) | KIF11PTGDR2CCNB2CDK1CCNB1 | |
| SCHEMBL2961361 | 0.75 | NR1H2 (0.62) | PTGDR2NR1H2NR1H3 | |
| SCHEMBL2961347 | 0.74 | PTGDR2 (0.44) | PTGDR2CDK5CDK5R1NR1H2NR1H3 | |
| SCHEMBL2952908 | 0.73 | PTGDR2 (0.51) | PTGDR2GSK3BCDK5CDK5R1EIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210685-A1 | Novel Substituted Indoles | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7754735-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1549634-A1 | NOVEL SUBSTITUTED INDOLES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2003101981-A1 | NOVEL SUBSTITUTED INDOLES | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210685-A1 | Novel Substituted Indoles | IDO1, IDO2, TPH1 | KIF11 2584/4885PTGDR2 429/4885TDO2 11/4885 |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | HRH2, HRH1, HCAR2 | KIF11 4239/4885PTGDR2 54/4885TDO2 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.